Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.
In September 2020, Dr. Reddy’s Lab and RDIF entered into partnership to conduct clinical trials and distribute the vaccine in the country. As part of the agreement the RDIF will supply 100 million doses of the Vaccine to the country upon approval.
“This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study,” Dr Reddy’s told the Bombay Stock Exchange in a filing on Saturday evening.
ALSO READ | Fake News: WHO Hasn’t Issued Any Guidance Against COVID-19 That Suggests Vinegar, Water And Salt As Remedy
Even though statements are being issued by both the parties regarding the trial and distributions of the vaccine, but it is unclear till now that how many participants will be enrolled and how many sites will be studying the vaccine’s safety and ability of developing the immune response against the corona virus.
After the testing is complete and the vaccine is approved, the RDIF will be supplying 100 million doses of Sputnik V to Dr. Reddy’s lab. As Sputnik V is a two-dose vaccine, the RDIF spokesperson made it clear in a statement that, 100 million doses are meant for 100 million people. As the Sputnik V contains two shots of different common cold Adenovirus.
In Russia around 40,000 subjects are going through phase three clinical trials of the Sputnik V vaccine and the UAE also started the phase 3 clinical trials of the vaccine last week.